FLT3靶向抗体药物偶联物有效清除急性髓系白血病干细胞
该研究探讨FLT3靶向抗体药物偶联物(ADC)能否清除静息白血病干细胞(LSC)。体外实验显示,携带DUBA的ADC比携带MMAF的ADC更有效杀伤细胞周期停滞的AML细胞;两种ADC在集落形成和长期培养起始细胞实验中均能清除白血病祖细胞,且不影响健康干细胞。
要点
- FLT3靶向ADC携带DUBA或MMAF均对AML LSC有强效活性。
- DUBA比微管毒素auristatin更有效杀伤细胞周期停滞的AML细胞。
- 两种ADC在可比剂量下不影响健康干细胞和祖细胞。
核心结论
- FLT3靶向ADC携带DUBA或MMAF对AML LSC具有强效活性,是值得进一步临床开发的有前景候选药物。
研究设计与样本
- 研究旨在探讨FLT3-20D9h3-ADC递送DUBA或MMAF能否清除静息LSC,采用体外干细胞实验及PDX细胞实验。
主要发现
- DUBA比微管靶向auristatin更有效杀伤细胞周期停滞的AML细胞。
- 20D9h3-DUBA在集落形成单位和长期培养起始细胞实验中成功清除患者细胞和PDX细胞中的白血病祖细胞。
- 20D9h3-DUBA完全阻止AML PDX白血病起始细胞在NSG小鼠中植入。
- 20D9h3-MMAF在植入实验中效果相似,但在集落实验中效果较不显著。
- 两种ADC在可比剂量下不影响健康干细胞和祖细胞。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Refractory disease and relapse are major challenges in acute myeloid leukemia (AML) therapy attributed to survival of leukemic stem cells (LSC). To target LSCs, antibody-drug conjugates (ADCs) provide an elegant solution, combining the specificity of antibodies with highly potent payloads. We aimed to investigate if FLT3-20D9h3-ADCs delivering either the DNA-alkylator duocarmycin (DUBA) or the microtubule-toxin monomethyl auristatin F (MMAF) can eradicate quiescent LSCs. We show here that DUBA more potently kills cell-cycle arrested AML cells compared to microtubule-targeting auristatins. Due to limited stability of 20D9h3-DUBA ADC in vivo, we analyzed both ADCs in advanced in vitro stem cell assays. 20D9h3-DUBA successfully eliminated leukemic progenitors in vitro in colony-forming unit and long-term culture initiating cell assays, both in patient cells and in patient-derived xenograft (PDX) cells. Further, it completely prevented engraftment of AML PDX leukemia-initiating cells in NSG mice. 20D9h3-MMAF had a similar effect in engraftment assays, but a less prominent effect in colony assays. Both ADCs did not affect healthy stem and progenitor cells at comparable doses providing the rationale for FLT3 as therapeutic LSC target. Collectively, we show that FLT3-directed ADCs with DUBA or MMAF have potent activity against AML LSCs and represent promising candidates for further clinical development.
引用
- Able M, Kasper MA, Vick B, et al. Effective eradication of acute myeloid leukemia stem cells with FLT3-directed antibody-drug conjugates. Leukemia. 2025. PMID: 39870768. doi:10.1038/s41375-024-02510-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。